Market Closed -
Nasdaq
04:30:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
1.69
USD
|
+1.50%
|
|
+3.68%
|
-3.43%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
9.049
|
9.655
|
16.13
|
10.65
|
7.915
|
7.227
|
-
|
-
|
Enterprise Value (EV)
1 |
9.049
|
9.655
|
16.13
|
10.65
|
7.915
|
7.227
|
7.227
|
7.227
|
P/E ratio
|
-
|
-1.09
x
|
-0.95
x
|
-0.41
x
|
-0.41
x
|
-0.74
x
|
-0.9
x
|
-0.99
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
1.29
x
|
31.9
x
|
-
|
47.6
x
|
1.61
x
|
2.13
x
|
1.69
x
|
-
|
EV / Revenue
|
1.29
x
|
31.9
x
|
-
|
47.6
x
|
1.61
x
|
2.13
x
|
1.69
x
|
-
|
EV / EBITDA
|
-3.28
x
|
-1.14
x
|
-1.36
x
|
-0.56
x
|
-0.62
x
|
-0.72
x
|
-0.61
x
|
-
|
EV / FCF
|
-
|
-1,132,254
x
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-0%
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
8.03
x
|
4.5
x
|
1.5
x
|
1.29
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
251
|
319
|
1,024
|
2,240
|
4,523
|
4,276
|
-
|
-
|
Reference price
2 |
36.00
|
30.30
|
15.75
|
4.755
|
1.750
|
1.690
|
1.690
|
1.690
|
Announcement Date
|
3/30/20
|
2/22/21
|
2/24/22
|
2/23/23
|
3/5/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
6.998
|
0.303
|
-
|
0.224
|
4.913
|
3.4
|
4.281
|
-
|
EBITDA
1 |
-2.761
|
-8.437
|
-11.85
|
-19.09
|
-12.69
|
-10
|
-11.8
|
-
|
EBIT
1 |
-3.657
|
-9.584
|
-12.49
|
-19.71
|
-13.32
|
-19.86
|
-22.91
|
-40.62
|
Operating Margin
|
-52.26%
|
-3,163.04%
|
-
|
-8,800%
|
-271.14%
|
-584.04%
|
-535.15%
|
-
|
Earnings before Tax (EBT)
1 |
-10.89
|
-8.241
|
-13.4
|
-20.28
|
-13.32
|
-19.81
|
-22.84
|
-40.58
|
Net income
1 |
-11.44
|
-8.241
|
-13.4
|
-20.28
|
-13.32
|
-19.81
|
-22.84
|
-40.58
|
Net margin
|
-163.49%
|
-2,719.8%
|
-
|
-9,051.34%
|
-271.04%
|
-582.57%
|
-533.61%
|
-
|
EPS
2 |
-
|
-27.90
|
-16.65
|
-11.55
|
-4.240
|
-2.290
|
-1.883
|
-1.705
|
Free Cash Flow
|
-
|
-8.527
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-2,814.19%
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/30/20
|
2/22/21
|
2/24/22
|
2/23/23
|
3/5/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
0.073
|
0.151
|
0.506
|
1.854
|
1.24
|
1.313
|
1.7
|
1.7
|
1.7
|
1.7
|
1.5
|
EBITDA
1 |
-3.394
|
-3.578
|
-3.779
|
-4.965
|
-4.936
|
-5.413
|
-4.422
|
-1.33
|
-2.944
|
-3.709
|
-2.5
|
-2.5
|
-2.5
|
-2.5
|
-2.7
|
EBIT
1 |
-3.481
|
-3.957
|
-3.926
|
-5.12
|
-5.094
|
-5.572
|
-4.72
|
-1.49
|
-3.251
|
-3.86
|
-3.3
|
-3.3
|
-3.3
|
-3.3
|
-3.5
|
Operating Margin
|
-
|
-
|
-
|
-
|
-6,978.08%
|
-3,690.07%
|
-932.81%
|
-80.37%
|
-262.18%
|
-293.98%
|
-194.12%
|
-194.12%
|
-194.12%
|
-194.12%
|
-233.33%
|
Earnings before Tax (EBT)
1 |
-3.724
|
-4.155
|
-4.116
|
-5.282
|
-5.219
|
-5.658
|
-4.805
|
-1.482
|
-3.219
|
-3.81
|
-3.3
|
-3.3
|
-3.3
|
-3.3
|
-3.5
|
Net income
1 |
-3.724
|
-4.155
|
-4.116
|
-5.282
|
-5.219
|
-5.658
|
-4.805
|
-1.482
|
-3.219
|
-3.81
|
-3.3
|
-3.3
|
-3.3
|
-3.3
|
-3.5
|
Net margin
|
-
|
-
|
-
|
-
|
-7,149.32%
|
-3,747.02%
|
-949.6%
|
-79.94%
|
-259.6%
|
-290.18%
|
-194.12%
|
-194.12%
|
-194.12%
|
-194.12%
|
-233.33%
|
EPS
2 |
-4.200
|
-3.750
|
-2.850
|
-3.600
|
-2.850
|
-2.400
|
-2.100
|
-0.5900
|
-1.000
|
-0.7000
|
-0.7200
|
-0.7100
|
-0.6900
|
-0.7000
|
-0.7300
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
10/21/21
|
2/24/22
|
4/21/22
|
7/21/22
|
10/20/22
|
2/23/23
|
4/20/23
|
8/14/23
|
10/31/23
|
3/5/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-8.53
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
4.480
|
6.740
|
10.50
|
3.680
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.07
|
0.09
|
0.14
|
0.51
|
0.16
|
1
|
1
|
-
|
Capex / Sales
|
0.96%
|
30.69%
|
-
|
227.23%
|
3.26%
|
29.41%
|
23.36%
|
-
|
Announcement Date
|
3/30/20
|
2/22/21
|
2/24/22
|
2/23/23
|
3/5/24
|
-
|
-
|
-
|
Last Close Price
1.69
USD Average target price
11.33
USD Spread / Average Target +570.61% Consensus |
1st Jan change
|
Capi.
|
---|
| -3.43% | 7.23M | | +1.51% | 42.75B | | +49.22% | 41.61B | | +8.57% | 41.34B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|